MINDMAZE THERAPEUTICS HOLDING, known as Relief Therapeutics Holding AG, is a commercial-stage biopharmaceutical company operating within the Health Care sector, specifically in the Pharmaceuticals industry. The company is recognized for its focus on identifying, developing, and commercializing drugs and therapies targeting rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders. With its headquarters situated in Geneva, Switzerland, Relief Therapeutics Holding AG has established itself as a global entity in the biopharmaceutical landscape.
The company’s stock is actively traded on the SIX Swiss Exchange, reflecting its engagement with the financial markets. As of September 15, 2026, the closing price of the company’s stock was recorded at 0.1542 CHF. This figure is notably close to the 52-week low of 0.1486 CHF, observed on August 25, 2026. In contrast, the 52-week high reached 4.49 CHF on October 7, 2025, indicating significant volatility in the stock’s performance over the past year.
Relief Therapeutics Holding AG’s market capitalization stands at 26,690,000 CHF, which provides insight into the company’s valuation within the market. The price-to-earnings (P/E) ratio is currently at -1.42, suggesting that the company is not yet profitable or that its earnings are negative. This metric is crucial for investors assessing the company’s financial health and future growth potential.
The company’s strategic focus on rare diseases positions it uniquely within the pharmaceutical industry, addressing unmet medical needs and potentially offering significant therapeutic advancements. Relief Therapeutics Holding AG’s commitment to innovation and development in this niche market underscores its role as a key player in the global biopharmaceutical sector.
For further information regarding Relief Therapeutics Holding AG’s activities, offerings, and strategic initiatives, stakeholders and interested parties are encouraged to visit their official website at www.relieftherapeutics.com . This platform provides comprehensive insights into the company’s ongoing projects, research endeavors, and future outlook in the realm of rare disease treatment.
